The burgeoning popularity of retatrutide, initially for diabetes , is creating significant interest within the United Kingdom , prompting a notable shift in peptide trends. Access these treatments remains a complex situation , with NHS coverage currently limited and private clinics offering prescriptions at a higher cost . Concerns are being raised